Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Gene Patents: Common Sense from Down Under

Credit - australiaphotos.co.uk

Oh, crikey! The U.S. Supreme Court is currently reviewing briefs to consider whether preparations of DNA molecules are patentable. Possibly unnoticed to the Justices is a recent decision from the Federal Court of Australia confirming the patentability of ‘isolated’ DNA. The Supreme Court may not take any notice of this Australian case, but those following so-called gene patents can learn a lot from the no-nonsense approach of Aussie patent law. The Australian case focuses its Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Parallel Importation: A Disincentive for Developing World Access to Medicines

Credit mckaysavage.

Parallel importation serves as a challenge to improving access to medicines in the developing world.  Parallel importation occurs when a country imports a product from a 3rd country to take advantage of a cheaper price than what is present for the same product in-country.  The imports then directly and unfairly competes with the same product sold by the rights holder on the local market. Unfortunately for those most in need of special access to medicine Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Brazil Patent Policy: At a Crossroads

Photo By: DigiDreamGrafix.com

The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions.  In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent.  Traditionally, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO IP Counsels Committee Conference: Spring 2013 Line-Up

San Diego

San Diego, California is the next site for the BIO IP Counsels Committee Conference.  On March 25, 2013, biotech IP counsel will gather for an event dedicated to providing in-house IP counsel opportunities to learn cutting edge issues, network with their peers, and to enjoy another great location.  Here is the session line-up and confirmed speakers with more speaker confirmations to come.  Visit BIO’s IP Counsels Committee Conference page to register and learn more. Pre-Conference Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patently Biotech’s Top 5 Articles of 2012

By Vectorportal

2012 has been an eventful year for biotech IP issues.  Below are the top 5 articles and from Patently Biotech in 2012.  Click on the links to read the full articles. 1.  The Real Reason Why Salk Refused to Patent the Polio Vaccine A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent.  Could you patent the sun?”  Many use this statement Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,